查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081840

栓塞治療市場：2026-2032 年全球市場預測，按栓塞劑類型、治療方法、栓塞持續時間、入路、臨床應用、最終用戶和患者年齡層分類。

Embolotherapy Market by Embolic Agent Type, Therapeutic Modality, Embolic Persistence, Access Route, Clinical Application, End User, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，栓塞療法市場將成長至 61.1 億美元，複合年成長率為 7.01%。

主要市場統計數據
基準年 2025 38億美元
預計年份：2026年 40.6億美元
預測年份 2032 61.1億美元
複合年成長率 (%) 7.01%

栓塞療法是介入放射學的一個重要分支，它利用影像引導導管人為地阻塞血管，從而達到治療效果。其臨床應用廣泛，包括經動脈化療栓塞和放射性栓塞治療肝細胞癌、子宮肌瘤栓塞、控制創傷相關出血、消化道出血、血管畸形、良性前列腺增生以及術前血管阻塞等，這些應用都支撐著栓塞療法的需求。

栓塞治療市場正受到微創手術的興起、癌症和心血管疾病負擔的加重以及栓塞劑（如彈簧圈、微球、顆粒、栓塞栓塞器和液體栓塞劑）日益普及的影響。醫院和門診介入實驗室正優先採用能夠提高手術精準度、減輕住院患者負擔、支持可重複治療效果並允許在複雜血管解剖結構內安全操作的技術。

栓塞治療領域的變革性變化

栓塞治療領域正從傳統的血管閉塞轉向精準栓塞，器械的選擇越來越注重與動態、病變生物學特徵以及後續臨床目標的契合度。藥物釋放型微球、校準微球、可脫卸彈簧圈、血管栓塞器和先進的液體栓塞劑正在拓展治療選擇，並實現更可預測的分佈、可控的釋放和標靶治療。

人工智慧在栓塞治療中的累積影響

人工智慧並非取代醫師的判斷，而是在整個栓塞治療流程中創造累積價值。在術前規劃階段，人工智慧驅動的影像工具可以輔助病灶檢測、血管分割、體積評估和治療模擬。在手術過程中，人工智慧驅動的影像重建、輻射劑量最佳化和導航輔助功能可以幫助臨床醫生應對複雜的解剖結構，並減少流程中的變異性。

主要區域洞察：亞太地區、北美地區、歐洲、拉丁美洲、中東和非洲

隨著介入性腫瘤學、中風相關血管治療、創傷管理和微創療法在中國、日本、印度、韓國和澳洲的普及，亞太地區正蓬勃發展。中國和印度受益於龐大的患者群體、日益沉重的癌症和心血管疾病負擔以及對醫院基礎設施的投入；而日本和韓國則憑藉成熟的影像技術和專業的培訓，迅速採用先進的影像引導技術。在澳大利亞，集中化的專家網路和循證臨床標準正在推動對成熟的栓塞器械和工作流程解決方案的需求。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

隨著印尼、泰國、馬來西亞、新加坡、越南和菲律賓等國加大對醫院現代化、癌症治療體系和介入放射學培訓的投資，東協市場的重要性日益凸顯。新加坡作為區域先進影像引導醫學和專科醫生培訓中心發揮重要作用，而隨著保險報銷體系、專科醫生招聘以及公立和私立醫院投資的改善，預計東協主要國家的介入手術量將會增加。

主要栓塞治療市場的國家/地區特定見解

美國憑藉其成熟的介入放射學實踐、腫瘤中心、創傷網路、門診手術系統以及廣泛的醫療設備，在栓塞療法的應用方面處於主導地位。另一方面，加拿大則強調在其省級醫療保健系統中提供循證醫學服務，並建立健全的轉診至三級醫療機構的網路。在墨西哥和巴西，私立醫院和都市區專科醫療中心的需求日益成長，尤其是在腫瘤、消化道出血、創傷和婦科領域，但服務可及性因保險公司組成和專科醫生集中程度而異。

為栓塞治療行業的領導者提供的實用建議

產業供應商應優先考慮臨床差異化，在腫瘤、女性健康、創傷、消化道出血、良性前列腺增生和血管畸形等領域創建真實世界數據、對比結果數據以及針對特定手術的價值提案。產品系列應兼顧高階精準栓塞劑和麵向新興市場的經濟型產品，同時確保安全性、可視性、輸送性和操作性能不受影響。

栓塞治療市場分析的調查方法

本研究採用整合的一手和二手資料方法，評估栓塞治療的需求促進因素、技術應用現況、競爭格局、臨床應用模式和區域可近性。一手數據包括直接參與栓塞手術和採購決策的介入放射科醫生、醫院採購利益相關人員、臨床專業人員、分銷商、保險公司以及醫療設備公司高管的觀點。

結論：栓塞治療的策略性展望

隨著標靶性、影像導引、微創治療策略（可減輕手術負擔並支持器官保留療法）在醫療保健系統中日益重要，栓塞術預計將繼續保持其重要性。腫瘤學、血管疾病管理、創傷治療、消化道出血治療、子宮肌瘤治療等領域的需求，以及栓塞術作為手術替代或輔助性治療的日益普及，進一步強化了該市場的戰略重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 栓塞治療市場：依栓塞劑類型分類

  • 線圈
  • 血管栓塞
  • 可拆卸氣球
  • 硬化劑
  • 液體黏合劑

第8章 栓塞治療市場：依治療方式分類

  • 支架輔助彈簧圈
  • 化療栓塞術
  • 三明治法

第9章 栓塞治療市場：栓塞持續時間

  • 暫時性栓塞劑
  • 永久性栓塞器

第10章 栓塞治療市場：以入路分類

  • 動脈
  • 經靜脈

第11章 栓塞治療市場：依臨床應用分類

  • 腫瘤學
  • 神經血管疾病
  • 周邊血管疾病
  • 婦科疾病
  • 泌尿系統疾病
  • 消化道出血

第12章 栓塞治療市場：依最終使用者分類

  • 醫院
  • 門診手術中心
  • 專科診所

第13章 栓塞治療市場：依病患年齡層別分類

  • 兒童
  • 成人
  • 老年人

第14章 栓塞治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章 栓塞治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 栓塞治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • Abbott Laboratories
  • ABK Biomedical Inc.
  • Acandis GmbH
  • Artio Medical Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • Cardinal Health Inc.
  • Cook Group Incorporated
  • Embolx Inc.
  • EndoBar Solutions, LLC
  • EndoShape Inc.
  • GE HealthCare Technologies Inc.
  • Guerbet SA
  • IMBiotechnologies Ltd.
  • Instylla Inc.
  • Johnson & Johnson Services Inc.
  • Kaneka Corporation
  • Koninklijke Philips NV
  • Medtronic plc
  • Merit Medical Systems Inc.
  • Penumbra Inc.
  • QT Vascular Ltd.
  • Shape Memory Medical Inc.
  • Sirtex Medical Limited
  • Stryker Corporation
  • Surefire Medical Inc.
  • Terumo Corporation
  • TriSalus Life Sciences Inc.
  • Vascular Solutions Inc.
Product Code: MRR-4308E1C8878D

The Embolotherapy Market is projected to grow by USD 6.11 billion at a CAGR of 7.01% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.80 billion
Estimated Year [2026] USD 4.06 billion
Forecast Year [2032] USD 6.11 billion
CAGR (%) 7.01%

Embolotherapy is a core interventional radiology discipline that uses image-guided catheter delivery to intentionally occlude blood vessels for therapeutic benefit. Demand is supported by established clinical use in hepatocellular carcinoma through transarterial chemoembolization and radioembolization, uterine fibroid embolization, trauma-related hemorrhage control, gastrointestinal bleeding, vascular malformations, benign prostatic hyperplasia, and preoperative devascularization.

The embolotherapy market is shaped by the shift toward minimally invasive procedures, rising oncology and cardiovascular disease burdens, and broader adoption of embolic agents such as coils, microspheres, particles, plugs, and liquid embolics. Hospitals and ambulatory interventional suites are prioritizing technologies that improve procedural precision, reduce inpatient burden, support repeatable outcomes, and enable safe navigation across complex vascular anatomies.

Transformative Shifts in the Embolotherapy Landscape

The embolotherapy landscape is moving from conventional vessel occlusion toward precision embolization, where device selection is increasingly matched to flow dynamics, lesion biology, and downstream clinical goals. Drug-eluting beads, calibrated microspheres, detachable coils, vascular plugs, and advanced liquid embolics are expanding treatment options while enabling more predictable distribution, controlled deployment, and targeted therapy.

Care delivery is also changing as interventional radiology teams integrate cone-beam CT, fusion imaging, navigation software, and multidisciplinary tumor boards to improve case planning and clinical decision-making. At the same time, reimbursement scrutiny, evidence expectations, and hospital value-analysis committees are pushing suppliers and providers to demonstrate clinical benefit, usability, supply reliability, procedural efficiency, and total cost-of-care advantages.

Cumulative Impact of Artificial Intelligence on Embolotherapy

Artificial intelligence is creating cumulative value across embolotherapy workflows rather than replacing physician judgment. In pre-procedure planning, AI-enabled imaging tools can support lesion detection, vessel segmentation, volumetric assessment, and treatment simulation. During procedures, AI-assisted image reconstruction, radiation-dose optimization, and navigation support can help clinicians manage complex anatomy and reduce workflow variability.

Post-procedure, machine learning can contribute to response assessment by analyzing imaging changes, tumor enhancement patterns, perfusion characteristics, and longitudinal outcomes. The strongest near-term opportunity is decision support that combines imaging, device characteristics, and patient risk factors. Adoption will depend on clinical validation, interoperability with angiography platforms, cybersecurity controls, explainable outputs, and transparent regulatory pathways for software as a medical device.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is gaining momentum as China, Japan, India, South Korea, and Australia expand interventional oncology, stroke-related vascular care, trauma management, and minimally invasive treatment access. China and India benefit from large patient pools, rising cancer and cardiovascular disease burdens, and hospital infrastructure investment, while Japan and South Korea show strong uptake of advanced image-guided technologies supported by mature imaging capacity and specialist training. Australia's centralized specialist networks and evidence-based clinical standards support demand for proven embolic devices and workflow solutions.

North America remains a high-adoption region due to established interventional radiology networks, broad availability of embolic devices, advanced angiography infrastructure, and clinical guideline integration. Europe benefits from strong tertiary care systems, oncology programs, specialist societies, and medical device regulation that emphasizes safety, clinical evidence, and post-market surveillance. Latin America is advancing through urban specialty centers in Brazil and Mexico, where private hospital investment and oncology service expansion are improving access, although availability continues to vary by payer coverage, procurement capacity, and trained workforce distribution.

The Middle East is expanding embolotherapy through tertiary hospitals, oncology investment, trauma care development, and medical tourism hubs, particularly across GCC markets. Africa remains more heterogeneous, with adoption concentrated in major referral hospitals and academic centers where imaging infrastructure, trained interventional radiologists, and device availability are improving. Across emerging regions, the most durable progress is linked to workforce training, reliable supply chains, reimbursement clarity, and access to modern angiography systems.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are increasingly relevant as Indonesia, Thailand, Malaysia, Singapore, Vietnam, and the Philippines invest in hospital modernization, cancer care capacity, and interventional radiology training. Singapore serves as a regional center for advanced image-guided care and specialist education, while larger ASEAN countries present procedure-volume potential as reimbursement pathways, specialist availability, and public-private hospital investment improve.

The GCC benefits from high healthcare spending, tertiary hospital networks, and strategic investment in oncology, emergency care, and minimally invasive specialties. The European Union provides a structured regulatory and procurement environment, where Medical Device Regulation compliance, clinical evidence, traceability, and post-market surveillance influence market access. BRICS countries combine substantial patient demand with uneven infrastructure maturity, creating opportunities for scalable product portfolios, localized training, and adaptable pricing strategies aligned with hospital capability.

G7 markets remain important for premium embolic agents, clinical research, evidence generation, reimbursement assessment, and early adoption of AI-enabled imaging and navigation. NATO-aligned healthcare systems, while not a commercial market bloc, often share procurement standards, emergency medicine priorities, trauma readiness requirements, and defense-related hemorrhage control needs that can support demand for embolization technologies used in acute bleeding management.

Key Country Insights for Major Embolotherapy Markets

The United States leads in embolotherapy adoption through mature interventional radiology practices, oncology centers, trauma networks, outpatient procedure capabilities, and broad device availability, while Canada emphasizes evidence-based access within provincial healthcare systems and strong tertiary care referral pathways. Mexico and Brazil show growing demand in private hospitals and urban specialty centers, particularly for oncology, gastrointestinal bleeding, trauma, and women's health applications, with access shaped by payer mix and specialist concentration.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established referral pathways, oncology programs, and strong specialist networks. Germany and France are important hubs for innovation, training, and advanced image-guided procedures, while the United Kingdom emphasizes guideline-driven adoption and health technology assessment. Italy and Spain support demand through active tertiary hospitals and interventional oncology programs. Russia retains demand across major urban hospitals but faces procurement, logistics, and supply-chain constraints that can affect availability of advanced embolic products.

China and India represent major expansion opportunities supported by large cancer and vascular disease burdens, expanding hospital capacity, and increasing interventional radiology training. Japan and South Korea are advanced technology adopters with strong imaging infrastructure, high procedural sophistication, and well-established hospital networks. Australia combines high clinical standards with centralized specialist care and public-private healthcare delivery, supporting demand for proven embolic devices, radiation-conscious imaging workflows, and integrated image-guided treatment solutions.

Actionable Recommendations for Embolotherapy Industry Leaders

Industry vendors should prioritize clinical differentiation by generating real-world evidence, comparative outcome data, and procedure-specific value propositions for oncology, women's health, trauma, gastrointestinal bleeding, benign prostatic hyperplasia, and vascular malformations. Product portfolios should address both premium precision embolics and cost-effective options for emerging markets without compromising safety, visibility, deliverability, or handling performance.

Manufacturers and providers should invest in physician training, proctoring, simulation, and digital case-planning tools to improve adoption and procedural consistency. Partnerships with hospitals, imaging technology providers, and AI software developers can strengthen ecosystem positioning. Supply-chain resilience, regulatory readiness, reimbursement evidence, post-market surveillance, and cybersecurity for connected workflow tools should be treated as strategic capabilities rather than back-office functions.

Research Methodology for Embolotherapy Market Analysis

The research approach integrates primary and secondary intelligence to evaluate embolotherapy demand drivers, technology adoption, competitive dynamics, clinical use patterns, and regional access conditions. Primary inputs include perspectives from interventional radiologists, hospital procurement stakeholders, clinical specialists, distributors, payers, and medical device executives with direct exposure to embolization procedures and purchasing decisions.

Secondary analysis draws from peer-reviewed clinical literature, regulatory databases, clinical guidelines, procedure coding references, hospital purchasing indicators, public health statistics, adverse event resources, and international disease-burden sources. Findings are validated through data triangulation, market-factor analysis, and consistency checks across procedure utilization signals, installed imaging capacity, regulatory status, reimbursement context, specialist availability, supply-chain conditions, and macroeconomic indicators.

Conclusion: Strategic Outlook for Embolotherapy

Embolotherapy is positioned for sustained relevance as healthcare systems favor targeted, image-guided, minimally invasive treatment strategies that can reduce surgical burden and support organ-preserving care. The market's strategic importance is reinforced by oncology needs, vascular disease management, trauma care, gastrointestinal bleeding treatment, uterine fibroid management, and expanding acceptance of embolization as a therapeutic alternative or adjunct to surgery.

Future competitiveness will depend on precision delivery, evidence generation, AI-enabled workflow integration, regulatory execution, and regional access strategies. Organizations that align device innovation with clinician training, payer expectations, reliable supply, and measurable patient outcomes will be best positioned to strengthen long-term relevance in the global embolotherapy market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Embolotherapy Market, by Embolic Agent Type

  • 7.1. Coils
  • 7.2. Vascular Plugs
  • 7.3. Detachable Balloons
  • 7.4. Sclerosants
  • 7.5. Liquid Glue

8. Embolotherapy Market, by Therapeutic Modality

  • 8.1. Stent-Assisted Coiling
  • 8.2. Chemoembolization
  • 8.3. Sandwich Technique

9. Embolotherapy Market, by Embolic Persistence

  • 9.1. Temporary Embolics
  • 9.2. Permanent Embolics

10. Embolotherapy Market, by Access Route

  • 10.1. Transarterial
  • 10.2. Transvenous

11. Embolotherapy Market, by Clinical Application

  • 11.1. Oncology
  • 11.2. Neurovascular Disorders
  • 11.3. Peripheral Vascular Disease
  • 11.4. Gynecological Conditions
  • 11.5. Urological Conditions
  • 11.6. Gastrointestinal Bleeding

12. Embolotherapy Market, by End User

  • 12.1. Hospitals
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Specialty Clinics

13. Embolotherapy Market, by Patient Age Group

  • 13.1. Pediatric
  • 13.2. Adult
  • 13.3. Geriatric

14. Embolotherapy Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Embolotherapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Embolotherapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Abbott Laboratories
  • 18.2. ABK Biomedical Inc.
  • 18.3. Acandis GmbH
  • 18.4. Artio Medical Inc.
  • 18.5. B. Braun SE
  • 18.6. Becton, Dickinson and Company
  • 18.7. Boston Scientific Corporation
  • 18.8. Canon Medical Systems Corporation
  • 18.9. Cardinal Health Inc.
  • 18.10. Cook Group Incorporated
  • 18.11. Embolx Inc.
  • 18.12. EndoBar Solutions, LLC
  • 18.13. EndoShape Inc.
  • 18.14. GE HealthCare Technologies Inc.
  • 18.15. Guerbet SA
  • 18.16. IMBiotechnologies Ltd.
  • 18.17. Instylla Inc.
  • 18.18. Johnson & Johnson Services Inc.
  • 18.19. Kaneka Corporation
  • 18.20. Koninklijke Philips N.V.
  • 18.21. Medtronic plc
  • 18.22. Merit Medical Systems Inc.
  • 18.23. Penumbra Inc.
  • 18.24. QT Vascular Ltd.
  • 18.25. Shape Memory Medical Inc.
  • 18.26. Sirtex Medical Limited
  • 18.27. Stryker Corporation
  • 18.28. Surefire Medical Inc.
  • 18.29. Terumo Corporation
  • 18.30. TriSalus Life Sciences Inc.
  • 18.31. Vascular Solutions Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EMBOLOTHERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL EMBOLOTHERAPY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL EMBOLOTHERAPY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL EMBOLOTHERAPY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL EMBOLOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL EMBOLOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COILS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COILS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COILS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR PLUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR PLUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR PLUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DETACHABLE BALLOONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DETACHABLE BALLOONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DETACHABLE BALLOONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SCLEROSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SCLEROSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SCLEROSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIQUID GLUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIQUID GLUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIQUID GLUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STENT-ASSISTED COILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STENT-ASSISTED COILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STENT-ASSISTED COILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOEMBOLIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOEMBOLIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOEMBOLIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SANDWICH TECHNIQUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SANDWICH TECHNIQUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SANDWICH TECHNIQUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TEMPORARY EMBOLICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TEMPORARY EMBOLICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TEMPORARY EMBOLICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PERMANENT EMBOLICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PERMANENT EMBOLICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PERMANENT EMBOLICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSARTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSARTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSARTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PERIPHERAL VASCULAR DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PERIPHERAL VASCULAR DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PERIPHERAL VASCULAR DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GYNECOLOGICAL CONDITIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GYNECOLOGICAL CONDITIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GYNECOLOGICAL CONDITIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UROLOGICAL CONDITIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UROLOGICAL CONDITIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UROLOGICAL CONDITIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GASTROINTESTINAL BLEEDING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GASTROINTESTINAL BLEEDING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GASTROINTESTINAL BLEEDING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GCC EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. GCC EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. GCC EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. G7 EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. G7 EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. G7 EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. NATO EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. NATO EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 174. NATO EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL EMBOLOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 192. CANADA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 193. CANADA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. CANADA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CANADA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 199. MEXICO EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 200. MEXICO EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 201. MEXICO EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. MEXICO EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. MEXICO EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 207. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 208. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 209. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. BRAZIL EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. GERMANY EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 231. FRANCE EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 232. FRANCE EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 233. FRANCE EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. FRANCE EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. FRANCE EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 239. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 240. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 241. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. RUSSIA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 247. ITALY EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 248. ITALY EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 249. ITALY EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 250. ITALY EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. ITALY EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. SPAIN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. SPAIN EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 255. SPAIN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 256. SPAIN EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 257. SPAIN EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. SPAIN EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. SPAIN EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 271. INDIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 272. INDIA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 273. INDIA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 274. INDIA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. INDIA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 279. JAPAN EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 280. JAPAN EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 281. JAPAN EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. JAPAN EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. JAPAN EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 287. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 288. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 289. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. AUSTRALIA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 295. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY EMBOLIC PERSISTENCE, 2018-2032 (USD MILLION)
  • TABLE 296. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY ACCESS ROUTE, 2018-2032 (USD MILLION)
  • TABLE 297. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY CLINICAL APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 298. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. SOUTH KOREA EMBOLOTHERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)